Клиническое значение результатов исследования DAPA HF (Dapagliflozin and prevention of adverse-outcomes in heart failure) для пациентов и врачей. Консенсус совета Экспертов

Journal "Medicine" Pub Date : 2021-03-02 DOI:10.31082/1728-452x-2021-223-1-2-14

Gulmira Alipova, Anna Bazarova, Nazira Bazarova, Rimma Bazarbekova, Gulnara Bedelbaeva, I. Guseva, Gulnara Junusbekova, Ainur Dossanova, Gulnar Jussupova, Murat Mukarov, Akmaral Nurbekova, Tatiana Oylarova, Zhannat Taubaldieva, S. Tereshchenko, Meyramgul Tundybaeva

{"title":"Клиническое значение результатов исследования DAPA HF (Dapagliflozin and prevention of adverse-outcomes in heart failure) для пациентов и врачей. Консенсус совета Экспертов","authors":"Gulmira Alipova, Anna Bazarova, Nazira Bazarova, Rimma Bazarbekova, Gulnara Bedelbaeva, I. Guseva, Gulnara Junusbekova, Ainur Dossanova, Gulnar Jussupova, Murat Mukarov, Akmaral Nurbekova, Tatiana Oylarova, Zhannat Taubaldieva, S. Tereshchenko, Meyramgul Tundybaeva","doi":"10.31082/1728-452x-2021-223-1-2-14","DOIUrl":null,"url":null,"abstract":"The article presents the results of the DAPA-HF study - evaluating the efficacy of dapagliflozin, used at a dose of 10 mg once a day, in addition to the standard treatment for patients with chronic heart failure with reduced left ventricular ejection fraction, compared to placebo. An analysis of current clinical recommendations related to this issue was carried out, the results of recent clinical studies and metaanalyses conducted were highlighted. Based on the results of the study, the need is postulated to optimize drug therapy of this category to patients with persistent symptoms of heart failure, despite standard therapy, with the addition of dapagliflozin to reduce the risk of cardiovascular death and hospitalizations for heart failure, improve the course of the disease. Keywords: chronic heart failure, dapagliflozin, low ejection fraction, effects of type 2 sodium-glucose co transporter inhibitors, diabetes mellitus.","PeriodicalId":14842,"journal":{"name":"Journal \"Medicine\"","volume":"23 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal \"Medicine\"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31082/1728-452x-2021-223-1-2-14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The article presents the results of the DAPA-HF study - evaluating the efficacy of dapagliflozin, used at a dose of 10 mg once a day, in addition to the standard treatment for patients with chronic heart failure with reduced left ventricular ejection fraction, compared to placebo. An analysis of current clinical recommendations related to this issue was carried out, the results of recent clinical studies and metaanalyses conducted were highlighted. Based on the results of the study, the need is postulated to optimize drug therapy of this category to patients with persistent symptoms of heart failure, despite standard therapy, with the addition of dapagliflozin to reduce the risk of cardiovascular death and hospitalizations for heart failure, improve the course of the disease. Keywords: chronic heart failure, dapagliflozin, low ejection fraction, effects of type 2 sodium-glucose co transporter inhibitors, diabetes mellitus.

查看原文本刊更多论文

这篇文章介绍了DAPA-HF研究的结果，该研究评估了达格列净的疗效，在标准治疗左心室射血分数降低的慢性心力衰竭患者的基础上，每天使用10mg的剂量，与安慰剂相比。对当前与此问题相关的临床建议进行了分析，并强调了最近进行的临床研究和荟萃分析的结果。根据本研究的结果，假设有必要优化这类患者的药物治疗，尽管有标准的治疗，但仍有持续的心衰症状，加入达格列净，以降低心血管死亡和心衰住院的风险，改善病程。关键词:慢性心力衰竭，达格列净，低射血分数，2型钠-葡萄糖共转运蛋白抑制剂的作用，糖尿病

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal "Medicine"

自引率

0.00%

发文量